Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10283082" target="_blank" >RIV/00216208:11110/14:10283082 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/14:00075662 RIV/00216208:11130/14:10283082 RIV/61989592:15110/14:33149134 RIV/00064203:_____/14:10283082 RIV/00064190:_____/14:#0000808
Result on the web
<a href="http://dx.doi.org/10.1016/j.urolonc.2013.09.011" target="_blank" >http://dx.doi.org/10.1016/j.urolonc.2013.09.011</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.urolonc.2013.09.011" target="_blank" >10.1016/j.urolonc.2013.09.011</a>
Alternative languages
Result language
angličtina
Original language name
Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines
Original language description
Objectives: The aim of this retrospective study was to analyze prognostic factors in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors (TKIs) sunitinib or sorafenib after progression on cytokine therapy. Materials andmethods: A national database of patients treated with targeted agents was used as the data source. A total of 319 patients treated with sunitinib (n = 181) or sorafenib (n = 138) after progression on cytokine therapy were analyzed. Results: Prognostic factors significantly associated with poor overall survival in a multivariable Cox model included the time from diagnosis to the start of treatment with TKIs <1 year, increased neutrophil counts, increased lactate dehydrogenase, and Eastern Oncology Cooperative Group performance status 2 or higher. The parameters showing statistically significant association with progression-free survival included time from diagnosis to the beginning of treatment with TKI <1 year, increased lactate dehydro
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Urologic Oncology: Seminars and Original Investigations
ISSN
1078-1439
e-ISSN
—
Volume of the periodical
32
Issue of the periodical within the volume
4
Country of publishing house
US - UNITED STATES
Number of pages
8
Pages from-to
488-495
UT code for WoS article
000335422300017
EID of the result in the Scopus database
—